List view / Grid view
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Japanese scientists have developed a lab-grown liver organoid that mimics human liver regeneration, offering a new platform to study fibrosis and test therapies.
For the first time, researchers have demonstrated that flipping an epigenetic ‘switch’ in memory cells can directly control whether a memory is expressed or silenced, offering new insights into how memories are stored and potentially altered.
Scientists have restored sperm production in mice with a genetic form of male infertility using mRNA delivered via lipid nanoparticles, with the hope of informing future treatments for non-obstructive azoospermia.
Scientists have linked rare mutations in SPNS1 to a previously unknown lipid recycling pathway in lysosomes, revealing how faulty fat processing can trigger muscle and liver disease.
Scientists have created a flexible brain implant, called SPIRAL, capable of delivering drugs to multiple regions with pinpoint accuracy.
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
6 October 2025 | By
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
New research using stem cell-derived kidney organoids reveals how APOL1 gene mutations disrupt mitochondrial function in kidney cells – potentially leading to new targeted treatments.
